Health & Biotech ‘Revenues and profitability will steadily increase’: Equity firm says undervalued EZZ set up for future growth July 27, 2022 Special Report: Equity firm Lodge Partners has forecasted revenue and profits to steadily increase for EZZ in FY23 as it… Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success July 26, 2022 Special Report: PharmAust’s clinical trials in canine cancers, human cancers, Covid-19 and MND/ASL could lead to multi-billion dollar opportunities, according… ASX Health Stocks: INOVIQ reports good study results; Mayne Pharma launches unique oral contraceptive July 26, 2022 Diagnostics and exosome specialist INOVIQ (ASX:IIQ) says that a feasibility study to evaluate the use of SubB2M has been completed. Osteopore delivers three straight quarters of growth in record financial performance July 25, 2022 Special Report: Aussie-listed med-tech Osteopore (ASX: OSX), just dropped the best quarterly result in the company’s history. Creso Pharma’s acquisition target lands deal with leading US online health marketplace July 25, 2022 Special Report: The deal between Creso’s acquisition target Sierra Sage Herbs could potentially open up a huge opportunity for new… Here are the Top 10 crucial trials coming up for ASX biotechs in 2022 July 25, 2022 What are the top 10 crucial clinical trials that are currently happening with ASX listed biotechs in 2022? Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism July 22, 2022 Special Report: The recent trial results success could pave the way to test other neurological illnesses, as well as an… ASX Health Stocks: Inoviq pockets another US patent, its second in a month July 22, 2022 Diagnostics and exosome specialist Inoviq (ASX:IIQ) has been granted a US patent for its hTERT test platform. Nutritional Growth Solutions just signed a key distribution deal in US July 21, 2022 Special Report: Nutritional Growth Solutions has increased the pace of its US rollout through a deal with the country’s largest… Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drug July 21, 2022 Special Report: Incannex has achieved approval to start a milestone clinical trial into its multi-use, anti-inflammatory drug to treat a… Next» « Previous